LENZ Therapeutics to Participate in Upcoming Investor Conferences
LENZ Therapeutics (Nasdaq: LENZ), a pre-commercial stage biopharmaceutical company developing the first aceclidine-based eye drop for presbyopia near vision improvement, has announced its participation in two major investor conferences.
The company will present at the TD Cowen 45th Annual Health Care Conference in Boston, with a corporate presentation scheduled for March 3rd, 2025, at 9:50am ET. Management will conduct one-on-one meetings from March 3rd through March 5th, 2025.
Additionally, LENZ will participate in the Leerink Partners Global Healthcare Conference in Miami, featuring a fireside chat on March 11th at 2:20pm ET, along with one-on-one meetings. The TD Cowen conference presentation will be available via live audio webcast, accessible through their website, with a 12-month replay period.
LENZ Therapeutics (Nasdaq: LENZ), un'azienda biofarmaceutica in fase pre-commerciale che sta sviluppando il primo collirio a base di aceclidina per il miglioramento della visione da vicino nella presbiopia, ha annunciato la sua partecipazione a due importanti conferenze per investitori.
L'azienda presenterà alla 45ª Conferenza Sanitaria Annuale TD Cowen a Boston, con una presentazione aziendale programmata per il 3 marzo 2025, alle 9:50 ET. La direzione condurrà incontri one-to-one dal 3 al 5 marzo 2025.
Inoltre, LENZ parteciperà alla Conferenza Globale sulla Salute di Leerink Partners a Miami, con una chiacchierata informale prevista per l'11 marzo alle 14:20 ET, insieme a incontri one-to-one. La presentazione della conferenza TD Cowen sarà disponibile tramite webcast audio dal vivo, accessibile attraverso il loro sito web, con un periodo di replay di 12 mesi.
LENZ Therapeutics (Nasdaq: LENZ), una empresa biofarmacéutica en etapa precomercial que está desarrollando la primera gota ocular a base de aceclidina para la mejora de la visión cercana en la presbicia, ha anunciado su participación en dos importantes conferencias para inversores.
La empresa presentará en la 45ª Conferencia Anual de Salud de TD Cowen en Boston, con una presentación corporativa programada para el 3 de marzo de 2025, a las 9:50 ET. La dirección llevará a cabo reuniones uno a uno del 3 al 5 de marzo de 2025.
Además, LENZ participará en la Conferencia Global de Atención Médica de Leerink Partners en Miami, con un chat informal el 11 de marzo a las 14:20 ET, junto con reuniones uno a uno. La presentación de la conferencia TD Cowen estará disponible a través de una transmisión de audio en vivo, accesible a través de su sitio web, con un período de repetición de 12 meses.
LENZ Therapeutics (Nasdaq: LENZ)는 노안 시력 개선을 위한 최초의 아세클리딘 기반 안약을 개발 중인 상업화 전 단계의 생명공학 회사로, 두 개의 주요 투자자 회의에 참여한다고 발표했습니다.
회사는 2025년 3월 3일 오전 9시 50분 ET에 보스턴에서 열리는 TD Cowen 제45회 연례 의료 회의에서 기업 발표를 할 예정입니다. 경영진은 2025년 3월 3일부터 5일까지 일대일 미팅을 진행합니다.
또한, LENZ는 마이애미에서 열리는 Leerink Partners 글로벌 의료 회의에 참여하여 3월 11일 오후 2시 20분 ET에 진행되는 화로 대화와 함께 일대일 미팅을 진행할 예정입니다. TD Cowen 회의 발표는 웹사이트를 통해 실시간 오디오 웹캐스트로 제공되며, 12개월 동안 다시 볼 수 있습니다.
LENZ Therapeutics (Nasdaq: LENZ), une entreprise biopharmaceutique en phase pré-commerciale développant le premier collyre à base d'aceclidine pour l'amélioration de la vision de près en cas de presbytie, a annoncé sa participation à deux grandes conférences pour investisseurs.
L'entreprise présentera à la 45e Conférence Annuelle de Santé TD Cowen à Boston, avec une présentation d'entreprise prévue pour le 3 mars 2025 à 9h50 ET. La direction organisera des réunions individuelles du 3 au 5 mars 2025.
De plus, LENZ participera à la Conférence Mondiale sur la Santé de Leerink Partners à Miami, avec une discussion informelle prévue le 11 mars à 14h20 ET, ainsi que des réunions individuelles. La présentation de la conférence TD Cowen sera disponible via un webinaire audio en direct, accessible via leur site web, avec une période de rediffusion de 12 mois.
LENZ Therapeutics (Nasdaq: LENZ), ein biopharmazeutisches Unternehmen in der prä-kommerziellen Phase, das die erste aceclidinbasierte Augentropfen zur Verbesserung der Nahsicht bei Presbyopie entwickelt, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen angekündigt.
Das Unternehmen wird auf der 45. jährlichen Gesundheitskonferenz von TD Cowen in Boston präsentieren, mit einer Unternehmenspräsentation, die für den 3. März 2025 um 9:50 Uhr ET geplant ist. Das Management wird vom 3. bis 5. März 2025 Einzelgespräche führen.
Zusätzlich wird LENZ an der Global Healthcare Conference von Leerink Partners in Miami teilnehmen, die am 11. März um 14:20 Uhr ET ein informelles Gespräch umfasst, sowie Einzelgespräche. Die Präsentation der TD Cowen-Konferenz wird über einen Live-Audio-Webcast verfügbar sein, der über die Website zugänglich ist, mit einer 12-monatigen Wiederholungsfrist.
- None.
- None.
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences:
TD Cowen 45th Annual Health Care Conference (Boston, MA)
Management is scheduled to provide a corporate presentation at Monday, March 3rd, 2025 at 9:50am ET, and will participate in one-on-one meetings from Monday, March 3rd through Wednesday, March 5th, 2025.
Leerink Partners Global Healthcare Conference (Miami, FL)
Management is scheduled to participate in a fireside chat on Tuesday, March 11th at 2:20pm ET and will participate in one-on-one meetings.
A live audio webcast of the TD Cowen 45th Annual Health Care Conference presentation can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 12 months following the event.
About LENZ Therapeutics
LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients with presbyopia. LENZ’s product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day”. LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.
Contacts:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com
FAQ
When is LENZ Therapeutics presenting at the TD Cowen Healthcare Conference in March 2025?
What is the schedule for LENZ's fireside chat at the Leerink Partners Conference 2025?
How long will the LENZ Therapeutics TD Cowen conference webcast be available for replay?
What type of eye drop treatment is LENZ Therapeutics developing?
Where can investors access LENZ Therapeutics' TD Cowen conference presentation?
